Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients with AdvSM. The primary endpoints were the maximum...

Descripción completa

Detalles Bibliográficos
Autores principales: DeAngelo, Daniel J., Radia, Deepti H., George, Tracy I., Robinson, William A., Quiery, Albert T., Drummond, Mark W., Bose, Prithviraj, Hexner, Elizabeth O., Winton, Elliott F., Horny, Hans-Peter, Tugnait, Meera, Schmidt-Kittler, Oleg, Evans, Erica K., Lin, Hui-Min, Mar, Brenton G., Verstovsek, Srdan, Deininger, Michael W., Gotlib, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674134/
https://www.ncbi.nlm.nih.gov/pubmed/34873347
http://dx.doi.org/10.1038/s41591-021-01538-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674134/
https://www.ncbi.nlm.nih.gov/pubmed/34873347
http://dx.doi.org/10.1038/s41591-021-01538-9

Ejemplares similares